Organisation paid for research Program year 2025 Source: CMS Open Payments

Panax Clinical Research

Neither a doctor nor a teaching hospital

Research payments

$5,816,235

244 payments

Through program year 2025, Panax Clinical Research is reported as receiving $5,816,235 in research payments, across 244 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$1,794,889	124
2024	Research	$1,756,181	32
2023	Research	$1,689,750	50
2022	Research	$80,703	14
2021	Research	$173,680	12
2020	Research	$3,968	4
2019	Research	$317,065	8

Breakdown

Who paid Research payments · program years 2019–2025

E.R. Squibb & Sons, L.L.C. $1,417,132 10 payments
AstraZeneca UK Limited $909,099 6 payments
Novartis Pharmaceuticals Corporation $817,292 26 payments
H. Lundbeck A S $669,795 19 payments
AstraZeneca AB $412,227 2 payments
Boehringer Ingelheim International GmbH $396,893 108 payments
Celgene Corporation $359,975 2 payments
Xeris Pharmaceuticals, Inc. $355,534 13 payments
Teva Pharmaceuticals USA, Inc. $130,250 11 payments
Emergent BioSolutions Inc. $125,369 2 payments

Studies the money was for Research payments · program years 2019–2025

Study to Assess Drug Levels and Safety of BMS-986278 in Healthy Participants and Participants With Different Degrees of Hepatic Impairment $695,050 2 payments
Study With Lu Af87908 in Healthy Participants and Participants With Alzheimer's Disease $618,345 16 payments
A Single Dose Non-Randomised Open-Label Parallel Group Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics Safety and Tolerability of AZD2693 $432,217 4 payments
A Phase I Multicentre Single Dose Non Randomised Open Label Parallel Group Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics Safety and Tolerability of AZD5004 $410,929 3 payments
A Phase 1, Multicenter, Open-label, Single -dose Study to Assess the Pharmacokinetics of Repotrectinib in Healthy Participants and those with Moderate, and Severe Hepatic Impairment $405,019 1 payment
Xp-8121-120 $355,534 13 payments
Hepatic Impairment $345,820 1 payment
A Single Dose Non Randomised Open Label Parallel Group Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics Safety and Tolerability of AZD2389 CAMPOLINA $305,616 2 payments
BI 456906 in NAFLD $238,182 2 payments
Phase 1 - Hepatic Impairment study in Healthy Volunteers $213,920 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.